A Phase 3 interventional study of somatropin and somatropin in Genetic Disorder and Noonan Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2023-08-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Genetic Diseases, Inborn · Novo Nordisk A/S.
Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2008, is one of 8 in phase 3, and was the 7th registered.
584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.
Browse Genetic Diseases, Inborn studies →None of the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S is open now. The open studies under Genetic Diseases, Inborn, anywhere →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 41 across 306 interventional studies indexed under Genetic Diseases, Inborn.
Median enrollment 51 across the 15 interventional studies, 238 across the 8 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.
Inclusion Criteria:
Drug: somatropin
Drug: somatropin
Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
Change in height SDS (Standard Deviation Score) (referenced to normal population)
Time frame: From baseline until final height is reached
Final height SDS (referenced to normal population)
Time frame: From baseline until final height is reached
Final height SDS (referenced to Noonan population)
Time frame: From baseline until final height is reached
Change in height SDS (referenced to Noonan population)
Time frame: From baseline until final height is reached
Number of subjects with final height SDS above - 2SDS (reference to normal population)
Time frame: When final height is reached
Proportion of subjects with final height SDS above - 2SDS (reference to normal population)
Time frame: When final height is reached
Adverse events
Time frame: From baseline until final height is reached
The record gives a start of Sep 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone